Hengrui Pharma and Novo Ink ~$2.6B Global Licensing Deal for HRS-1596

Shots: Hengrui Pharma has entered into a license agreement with Novo for HRS-1596, a P-I-ready GLP-1 receptor & gastric inhibitory polypeptide receptor dual agonist, with potential for QW oral dosing As per the deal, Novo will obtain exclusive rights to develop, manufacture & commercialize HRS-1596 globally, excl. Mainland China, the Hong Kong SAR, the Macao…

ByRidhi RastogiSeptember 29, 2026

The CHMP Recommends Novo’s Frehemgo (Denecimig) for Haemophilia A

Shots: The CHMP has recommended Frehemgo (QM, Q2W or QW) to treat haemophilia A, with or without inhibitors, in adults & children, based on the FRONTIER program; launch is expected in the first EU countries in Q4’26 & broadly across the EU starting early 2027 FRONTIER 2 trial showed Frehemgo significantly reduced annualized bleeding rates…

ByRidhi RastogiSeptember 18, 2026

Orbis Medicines and Novo Partner on Oral Macrocycle Drugs in a ~$1.4B Deal

Shots: Orbis Medicines has entered into a strategic collaboration & license agreement with Novo to discover & develop next-generation oral macrocycle therapeutics for cardiometabolic diseases As per the deal, Orbis will receive ~$1.4B in upfront, and development & commercial milestone payments, plus tiered royalties on future product sales, while Novo will also make a strategic…

ByRidhi RastogiSeptember 17, 2026

Hengrui Pharma and Novo Ink ~$2.6B Global Licensing Deal for HRS-1596

The CHMP Recommends Novo’s Frehemgo (Denecimig) for Haemophilia A

Orbis Medicines and Novo Partner on Oral Macrocycle Drugs in a ~$1.4B Deal

Contact US

FOLLOW US